The LINC01315-encoded Small Protein YAPer-ORF Competes with PRP4k to Hijack YAP Signaling to Aberrantly Promote Cell Growth

Overview

Journal Cell Death Differ

Specialty Cell Biology

Date 2025 Feb 17

PMID 39962243

Authors

Zhu Xie

Chao Li

Rui Huang

Bo Wu

Qian Huang

Zhe Zhang

Tongjin Zhao

Lingqian Wu

Chengtao Li

Jianfeng Shen

Hongyan Wang

Affiliations

Soon will be listed here.

Abstract

The dysregulation of YAP activity is implicated in abnormal organ size and the pathogenesis of diverse diseases, including cancer. However, the functional regulation of YAP activity by lncRNA-encoded peptides remains elusive. In this study, we report the identification of a small protein (93 aa) encoded by the lncRNA LINC01315. This small protein, termed YAPer-ORF, preferentially interacted with GNAQ/11 mutants to augment YAP activity. Mechanistically, YAPer-ORF was located in the nucleus and competed with YAP to bind the nuclear kinase PRP4K to hinder YAP phosphorylation. This decreased phosphorylation of YAP by YAPer-ORF promoted YAP retention in the nucleus and facilitated the expression of downstream target genes such as CCND1. In both cancerous and noncancerous models, YAPer-ORF prominently drove cell proliferation in a CCND1-dependent manner. Notably, cardiac-specific genetic knock-in of the human YAPer-ORF in mice significantly increased heart size through increased cardiomyocyte proliferation, underscoring the role of YAPer-ORF in cell proliferation. Moreover, treatment with an anti-YAPer-ORF neutralizing antibody effectively suppressed uveal melanoma growth, highlighting the therapeutic potential of targeting YAPer-ORF. These findings collectively establish YAPer-ORF as a critical regulator of YAP activity, further highlighting the disruption of YAPer-ORF activity as a potential therapeutic strategy against YAP-driven human cancers and developmental diseases.

References

Zheng Y, Pan D . The Hippo Signaling Pathway in Development and Disease. Dev Cell. 2019; 50(3):264-282. PMC: 6748048. DOI: 10.1016/j.devcel.2019.06.003. View

Dey A, Varelas X, Guan K . Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat Rev Drug Discov. 2020; 19(7):480-494. PMC: 7880238. DOI: 10.1038/s41573-020-0070-z. View

Moya I, Halder G . Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine. Nat Rev Mol Cell Biol. 2018; 20(4):211-226. DOI: 10.1038/s41580-018-0086-y. View

Zhang H, Ramakrishnan S, Triner D, Centofanti B, Maitra D, Gyorffy B . Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1. Sci Signal. 2015; 8(397):ra98. PMC: 4818013. DOI: 10.1126/scisignal.aac5418. View

Liu C, Wu Y, Ma J . Interaction of non-coding RNAs and Hippo signaling: Implications for tumorigenesis. Cancer Lett. 2020; 493:207-216. DOI: 10.1016/j.canlet.2020.08.012. View

Tu C, Yang K, Wan L, He J, Qi L, Wang W . The crosstalk between lncRNAs and the Hippo signalling pathway in cancer progression. Cell Prolif. 2020; 53(9):e12887. PMC: 7507458. DOI: 10.1111/cpr.12887. View

Ransohoff J, Wei Y, Khavari P . The functions and unique features of long intergenic non-coding RNA. Nat Rev Mol Cell Biol. 2017; 19(3):143-157. PMC: 5889127. DOI: 10.1038/nrm.2017.104. View

Ponting C, Oliver P, Reik W . Evolution and functions of long noncoding RNAs. Cell. 2009; 136(4):629-41. DOI: 10.1016/j.cell.2009.02.006. View

Wilusz J, Sunwoo H, Spector D . Long noncoding RNAs: functional surprises from the RNA world. Genes Dev. 2009; 23(13):1494-504. PMC: 3152381. DOI: 10.1101/gad.1800909. View

10.

Ruiz-Orera J, Messeguer X, Subirana J, Alba M . Long non-coding RNAs as a source of new peptides. Elife. 2014; 3:e03523. PMC: 4359382. DOI: 10.7554/eLife.03523. View

11.

Mackowiak S, Zauber H, Bielow C, Thiel D, Kutz K, Calviello L . Extensive identification and analysis of conserved small ORFs in animals. Genome Biol. 2015; 16:179. PMC: 4568590. DOI: 10.1186/s13059-015-0742-x. View

12.

Anderson D, Anderson K, Chang C, Makarewich C, Nelson B, McAnally J . A micropeptide encoded by a putative long noncoding RNA regulates muscle performance. Cell. 2015; 160(4):595-606. PMC: 4356254. DOI: 10.1016/j.cell.2015.01.009. View

13.

Nelson B, Makarewich C, Anderson D, Winders B, Troupes C, Wu F . A peptide encoded by a transcript annotated as long noncoding RNA enhances SERCA activity in muscle. Science. 2016; 351(6270):271-5. PMC: 4892890. DOI: 10.1126/science.aad4076. View

14.

Matsumoto A, Pasut A, Matsumoto M, Yamashita R, Fung J, Monteleone E . mTORC1 and muscle regeneration are regulated by the LINC00961-encoded SPAR polypeptide. Nature. 2016; 541(7636):228-232. DOI: 10.1038/nature21034. View

15.

Jiao S, Wang H, Shi Z, Dong A, Zhang W, Song X . A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell. 2014; 25(2):166-80. DOI: 10.1016/j.ccr.2014.01.010. View

16.

Zhang Z, Lin Z, Zhou Z, Shen H, Yan S, Mayweg A . Structure-Based Design and Synthesis of Potent Cyclic Peptides Inhibiting the YAP-TEAD Protein-Protein Interaction. ACS Med Chem Lett. 2014; 5(9):993-8. PMC: 4160762. DOI: 10.1021/ml500160m. View

17.

Carvajal R, Sacco J, Jager M, Eschelman D, Olofsson Bagge R, Harbour J . Advances in the clinical management of uveal melanoma. Nat Rev Clin Oncol. 2023; 20(2):99-115. DOI: 10.1038/s41571-022-00714-1. View

18.

Van Raamsdonk C, Griewank K, Crosby M, Garrido M, Vemula S, Wiesner T . Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010; 363(23):2191-9. PMC: 3107972. DOI: 10.1056/NEJMoa1000584. View

19.

Yu F, Luo J, Mo J, Liu G, Kim Y, Meng Z . Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell. 2014; 25(6):822-30. PMC: 4075337. DOI: 10.1016/j.ccr.2014.04.017. View

20.

Feng X, Degese M, Iglesias-Bartolome R, Vaque J, Molinolo A, Rodrigues M . Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell. 2014; 25(6):831-45. PMC: 4074519. DOI: 10.1016/j.ccr.2014.04.016. View